Browse CCR1

Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for a C-C type chemokine. Binds to MIP-1-alpha, MIP-1-delta, RANTES, and MCP-3 and, less efficiently, to MIP-1-beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. Responsible for affecting stem cell proliferation.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0002407 dendritic cell chemotaxis
GO:0002521 leukocyte differentiation
GO:0002548 monocyte chemotaxis
GO:0002573 myeloid leukocyte differentiation
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002763 positive regulation of myeloid leukocyte differentiation
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006887 exocytosis
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0010959 regulation of metal ion transport
GO:0030099 myeloid cell differentiation
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030282 bone mineralization
GO:0030316 osteoclast differentiation
GO:0030335 positive regulation of cell migration
GO:0030500 regulation of bone mineralization
GO:0030502 negative regulation of bone mineralization
GO:0030595 leukocyte chemotaxis
GO:0031214 biomineral tissue development
GO:0032103 positive regulation of response to external stimulus
GO:0036336 dendritic cell migration
GO:0040017 positive regulation of locomotion
GO:0043270 positive regulation of ion transport
GO:0043410 positive regulation of MAPK cascade
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045672 positive regulation of osteoclast differentiation
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:0070167 regulation of biomineral tissue development
GO:0070168 negative regulation of biomineral tissue development
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070838 divalent metal ion transport
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0071677 positive regulation of mononuclear cell migration
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0090025 regulation of monocyte chemotaxis
GO:0090026 positive regulation of monocyte chemotaxis
GO:0097529 myeloid leukocyte migration
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001637 G-protein coupled chemoattractant receptor activity
GO:0001653 peptide receptor activity
GO:0004435 phosphatidylinositol phospholipase C activity
GO:0004620 phospholipase activity
GO:0004629 phospholipase C activity
GO:0004896 cytokine receptor activity
GO:0004950 chemokine receptor activity
GO:0008081 phosphoric diester hydrolase activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0016298 lipase activity
GO:0016493 C-C chemokine receptor activity
GO:0019955 cytokine binding
GO:0019956 chemokine binding
GO:0019957 C-C chemokine binding
GO:0035717 chemokine (C-C motif) ligand 7 binding
GO:0042578 phosphoric ester hydrolase activity
GO:0071791 chemokine (C-C motif) ligand 5 binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins
Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CCR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26056232Breast CarcinomaInhibit immunityPulmonary metastasis of breast cancer cells is promoted by a distinct population of macrophages, metastasis-associated macrophages (MAMs), which originate from inflammatory monocytes (IMs) recruited by the CC-chemokine ligand 2 (CCL2). We demonstrate here that, through activation of the CCL2 receptor CCR2, the recruited MAMs secrete another chemokine ligand CCL3. Genetic deletion of CCL3 or its receptor CCR1 in macrophages reduces the number of lung metastasis foci, as well as the number of MAMs accumulated in tumor-challenged lung in mice.
29581358colorectal carcinomaPromote immunityConcurrent transcriptome analysis of epithelial cells, stromal cells, and T cell subsets obtained from carcinomatous and normal intestinal samples from patients revealed a distinct gene expression signature in colorectal adenocarcinoma-associated Tregs, with overexpression of CCR1, CCR8, and TNFRSF9, whereas their ligands CCL4 and TNFSF9 were found upregulated in cancerous epithelium.
18645037HepatomaPromote immunity (infiltration)Tumor-infiltrating DCs expressed chemokine receptors CCR1 and CCR5, and T cells and macrophages expressed CCL3, a ligand for CCR1 and CCR5. Thus, we provide definitive evidence indicating that CCR1 and CCR5 and their ligand CCL3 play a crucial role in the regulation of intratumoral DC accumulation and the subsequent establishment of tumor immunity following induction of tumor apoptosis by suicide genes.
20663902Hepatocellular CarcinomaPromote immunityDeficiency of CCR1 impairs accumulation of CD11c(+), CD4(+), and CD8(+) cells in RFA-treated tumors. Furthermore, in IFN-gamma-enzyme-linked immunospot assay, ECI301 augmented tumor-specific responses after RFA whereas deficiency of CCR1 abolished this augmentation.
Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6220.0864
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3070.852
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8470.46
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1830.721
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4630.683
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9990.457
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0420.934
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2170.883
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1540.925
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0140.425
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0650.605
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0250.884
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCR1
Namechemokine (C-C motif) receptor 1
Aliases MIP1aR; CD191; SCYAR1; CMKBR1; CKR1; HM145; C-C CKR-1; CC-CKR-1; CCR-1; LD78 receptor; MIP-1alpha-R; RANTES ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.